Purpose: To review and summarize the latest developments in the diagnosis and management of myopic choroidal neovascularization (mCNV).
Methods: A review of the literature was performed, focusing on tests and investigations for diagnosing mCNV, as well as the key treatment options available for mCNV.
Results: Standard essential tests and investigations for diagnosing mCNV include spectral-domain optical coherence tomography for screening, fluorescein angiography for confirmation, and indocyanine green angiography and fundus autofluorescence for providing supplementary information. The current first line treatment of mCNV is the use of anti-vascular endothelial growth factor therapy.
Conclusion: Various investigations can assist the differentiation of mCNV from other coexisting retinal pathologies associated with myopia or choroidal neovascularization resulting from other causes. Prompt use of anti-vascular endothelial growth factor therapy has good efficacy and safety in the treatment of mCNV.